Aprogen Healthcare & Games Inc. Overview
APTOCROM is a very small KOSDAQ-listed company inside the Aprogen biopharmaceutical group, which is controlled by Kim Jae-seop through his holding company G-Base. Its stated operating businesses are wholesale and retail distribution of pharmaceuticals (dermatologicals, gastrointestinal drugs, tonics and antibiotics) and leasing of owned real estate, machinery and equipment. Group-level reporting since 2020 has described its function as sales of pharmaceuticals and asset leasing. In practice, its economic profile is dominated by its role as a group financing vehicle rather than by operations. It carries a balance sheet of roughly KRW 320 bn against annual revenue under KRW 10 bn. It has channeled large sums into parent Aprogen's biosimilar programs: KRW 50 bn to trastuzumab biosimilar AP063 in 2023 and a KRW 70 bn cost-sharing commitment to adalimumab biosimilar AP096 in 2024. In August 2025 it added blockchain and virtual-asset activities to its articles of incorporation. Its equity story therefore turns on related-party asset recovery rather than on distribution economics.
Company's own description (from filings)
The Q1 2026 quarterly report filed on KIND describes the company (formerly AP Healthcare) as founded in February 1998 and engaged in pharmaceutical wholesale/retail and leasing (KIND Q1 2026 report, filed 14 May 2026). An August 2025 Asia Economy article summarizing disclosures was more specific. It described the pharmaceutical business as distribution and sale centered on external-use (dermatological) preparations, digestive-system drugs, tonics/nutritional preparations and antibiotic preparations. It described the leasing business as rental of owned real estate, machinery and equipment (Asia Economy, 11 Aug 2025).
Business model and revenue model
| Dimension | Characterization | Basis |
|---|---|---|
| Revenue model | Predominantly product resale (merchandise distribution) plus rental income; no subscription or licensing revenue disclosed | Filing descriptions, 2025–2026 |
| Product vs. service mix | Product distribution plus leasing; exact split not publicly disclosed in sources reviewed | — |
| Value-chain position | Downstream intermediary (wholesale/retail) in Korean pharmaceutical distribution; asset lessor | Filings |
| Customer types | Not publicly disclosed (typical counterparties for Korean pharmaceutical wholesalers are pharmacies; clinics and hospitals) | — |
| End-markets | South Korean domestic pharmaceutical market; domestic commercial real-estate rental (Seongnam) | Filings; KIND asset tables |
| Related-party economic interests | Revenue-linked "dividend" rights on AP096 (adalimumab biosimilar) under a KRW 70 bn cost-sharing contract with Aprogen; prior KRW 50 bn funding of AP063 (trastuzumab biosimilar); holdings of Aprogen convertible bonds | Dealsite, 20 Sep 2024; NewDaily, 23 Sep 2024; DigitalToday, 31 Mar 2026 |
| New statutory business objectives | Blockchain and virtual-asset business, blockchain/virtual-asset investment, blockchain/virtual-asset finance, and ancillary services/installation, added at the 22 Aug 2025 EGM | Asia Economy, 11 Aug 2025 |
Legacy businesses (pre-2024)
Before it became a pure distribution/leasing entity, the company (as Aprogen H&G) was described by aggregators as a mobile-game publisher that also provided domestic wireless lighting-control services and telecommunications/wireless solutions (Morningstar; CB Insights). Statbase's legacy management list includes a head of a Light Control Division, a head of a Wireless Solution Business Division and an R&D Center chief, consistent with that profile. The largest legacy game title was the mobile game Fortress M. Its publishing contract was terminated early in February 2021, removing about KRW 7.6 bn of sales; the then-parent Aprogen Pharmaceuticals said this equalled 15% of its own consolidated revenue. Management said it would offset the gap by publishing Trove and Dragon Raja Origin and further titles (Asia Economy English, 19 Feb 2021). The FY2025 revenue decline was attributed only to a "slowdown in a subsidiary's business," and the subsidiary was not named in the excerpts reviewed (FY2025 earnings-variance disclosure, 27 Feb 2026).
Independent characterization
On the numbers, APTOCROM's operating businesses are sub-scale. Consolidated FY2025 revenue was KRW 9.81 bn with an operating loss of KRW 2.29 bn, against total assets of about KRW 320 bn (FY2025 audited summary, 30 Mar 2026). An asset-to-revenue ratio above 30x means the operating business is not the main driver of value. What drives value is the recoverability of (i) related-party claims on Aprogen biosimilar programs, (ii) Aprogen-issued securities (such as the KRW 40 bn 27th-series CB it is selling), and (iii) its Seongnam real estate. Analytically, it behaves like a captive treasury or holding vehicle of the Aprogen group, with a small distribution business attached. The renaming to APTOCROM alongside a crypto/blockchain charter amendment fits a 2025 KOSDAQ pattern: other small caps such as Hyper Corporation, Parataxis Korea and Someage saw share-price spikes after announcing virtual-asset pivots (Asia Economy, 11 Aug 2025). No operating crypto revenue has been disclosed.
Strategy
The company has published no investor-day material and no strategy narrative from its annual report was retrievable. The strategy is therefore reconstructed from its disclosed actions over the last 24 months:
Context: the reverse split coincided with a broader rush of capital reductions. Between 1 Jan and 26 Mar 2026, 82 such decisions were filed on KOSPI and KOSDAQ, against 19 in the same period of 2025. Media linked the surge to regulators' stated intent to push "coin stocks" (shares below KRW 1,000) out of the market (Daum/news, 30 Mar 2026). APTOCROM traded at about KRW 164–193 before the split.
Medium-term financial targets and guidance: none published. ESG commitments and cost programs: none disclosed.
Product Portfolio
| Business line | Offering | Description / status | Target customer | Launch / version | Pricing | Source |
|---|---|---|---|---|---|---|
Pharmaceutical distribution | Dermatological (external-use) preparations | Distributed and sold; brands not disclosed | — | — | — | Asia Economy, 11 Aug 2025 |
Pharmaceutical distribution | Digestive-system drugs | Distributed and sold; brands not disclosed | — | — | — | Same |
Pharmaceutical distribution | Tonics / nutritional preparations | Distributed and sold; brands not disclosed | — | — | — | Same |
Pharmaceutical distribution | Antibiotic preparations | Distributed and sold; brands not disclosed | — | — | — | Same |
Leasing | Real estate (land and buildings, Seongnam) | Investment-property rental; land carrying value ~KRW 3.57 bn, buildings ~KRW 4.74 bn (Q1 2026 report table) | Commercial tenants (not named) | Ongoing | Lease rates not disclosed | KIND Q1 2026 report |
Leasing | Machinery and equipment | Rental of owned equipment | — | Ongoing | — | Asia Economy, 11 Aug 2025 |
Biosimilar economic interest | AP096 (adalimumab / Humira biosimilar) | Cost-sharing investor; entitled to sales-linked dividends after commercialization; parent guided clinical supply in H1 2025, trials to 2027, launch as early as 2028 | — | Development stage | KRW 70 bn commitment | Dealsite, 20 Sep 2024 |
Biosimilar economic interest | AP063 (trastuzumab / Herceptin biosimilar) | KRW 50 bn development funding in 2023; parent ran a global Phase 3 in 19 countries / 147 sites / 720 patients | — | Phase 3 (parent) | — | NewDaily, 23 Sep 2024; Asia Economy, 27 Jul 2023 |
New business (chartered) | Blockchain / virtual-asset business, investment and finance | Added to articles Aug 2025; no product, licence or revenue disclosed | — | Not launched (as far as disclosed) | — | Asia Economy, 11 Aug 2025 |
Legacy (historical) | Mobile game publishing (Fortress M; Trove; Dragon Raja Origin) | — | Consumers | 2020–2021 | — | Asia Economy English, 19 Feb 2021 |
Legacy (historical) | Wireless lighting-control services; wireless/telecom solutions | — | B2B | Pre-2017 | — | Morningstar; CB Insights |
“—” = not publicly disclosed.
Financial Narrative
Basis: K-IFRS consolidated, KRW bn, fiscal years ending 31 December. FY2025 uses the audited figures reported with the AGM results (30 Mar 2026). FY2024 uses the comparative column of the FY2025 earnings-variance disclosure (27 Feb 2026). FY2018–FY2019 context appears in 6.6.
Income statement
Notes and source conflicts:
FY2025 pre-tax figure: (−KRW 6.43 bn) is from the preliminary disclosure.
Separate (parent-only) FY2025: revenue KRW 7.40 bn, operating loss KRW 1.16 bn, net loss KRW 3.47 bn, EPS −KRW 16 (AGM results, 30 Mar 2026).
Gross profit: Statbase reports a TTM gross profit of about KRW 1.71 bn on about KRW 9 bn of TTM revenue to 31 Mar 2026 (≈19% gross margin).
EPS after the reverse split: Judal shows trailing EPS of KRW 3,299 and P/E of 0.57x (Oct 2026). That implies a large positive H1 2026 net profit, perhaps from a non-operating gain. Treat it with caution.
Growth
The FY2019–FY2025 CAGR is computed from FY2019 revenue of KRW 21.9 bn (Asia Economy, 28 Jan 2020) and FY2025 revenue of KRW 9.81 bn. Simply Wall St separately reports average annual revenue growth of 11.8% over its look-back window (TTM to 30 Sep 2025). That conflicts directionally with the FY2019–FY2025 trajectory because the window and base years differ.
Balance sheet
Additional balance-sheet data points:
Cash and equivalents: not publicly disclosed in sources reviewed. At end-Q2 2024, consolidated current assets were about KRW 24 bn (NewDaily, 23 Sep 2024).
Total debt (short/long split): not fully disclosed. The Q1 2026 report lists secured short-term borrowings of KRW 3.5 bn from Kookmin Bank (collateral: PP&E land/buildings) and KRW 2.0 bn from Hana Bank (collateral: investment-property land/buildings), with collateral of KRW 9.36 bn set on each (KIND Q1 2026 report excerpt). The KRW 40 bn 6th-series BW issued in July 2023 was "partially redeemed" by Q1 2026, with original maturity 25 Jul 2026.
Net debt: not computable without a verified cash figure. The low liabilities (KRW 13.9 bn total at FY2025) suggest gross debt is small relative to equity.
Goodwill & intangibles: not publicly disclosed in sources reviewed.
Working capital: not publicly disclosed in sources reviewed.
Related-party/financial assets: the company held Aprogen's KRW 40 bn 27th-series CB, under a sale agreement since April 2024 (DigitalToday, 31 Mar 2026). It also funded KRW 50 bn for AP063 (2023) and committed KRW 70 bn for AP096 (2024–2025).
Capital reduction: The 20:1 consolidation approved on 30 Mar 2026 reduces share capital from about KRW 110.4 bn to about KRW 5.5 bn in order to offset accumulated deficits (Dealsite, 23 Feb 2026). This changes equity composition, not total equity.
Cash flow
Notes: Cash-flow statements were not accessible. For the 27th CB sale, the contractual receipts are KRW 2 bn (5 Apr 2024) and KRW 15 bn (28 Oct 2024) in FY2024, then KRW 5 bn (8 Jan 2025) and KRW 2 bn (24 Oct 2025) in FY2025. The KRW 16 bn balance was rescheduled to 17 Apr 2026, extendable to 30 Jun 2026 (DigitalToday, 31 Mar 2026). The FY2024 offering was planned at KRW 50 bn, with uses of KRW 38.4 bn operating funds (of which KRW 35 bn for AP096), KRW 11 bn debt repayment (BW put) and KRW 0.6 bn other (Dealsite, 20 Sep 2024). There were no dividends; Simply Wall St reports no dividend history.
Ratios
Not computable from verified data: ROIC, current ratio, net debt/EBITDA, interest coverage, cash conversion cycle. Simply Wall St shows ROE of −21.61% and net margin of −549.87% on a TTM basis to 30 Sep 2025. That window includes the heavy Q4 2024 losses and differs from the fiscal-year figures above.
Historical context (pre-FY2021)
FY2019 is from Asia Economy English (28 Jan 2020). FY2018 revenue and operating income are back-computed from the reported FY2019 growth rates (+12.7% revenue; operating loss up 269.5%) and are approximate.
Trend commentary
-
Shrinking operating base. Revenue has fallen from about KRW 21.9 bn (FY2019, when games were still material) to KRW 16.4 bn (FY2024) and KRW 9.8 bn (FY2025). The 40% FY2025 drop was attributed to subsidiary slowdown (27 Feb 2026 disclosure). The loss of Fortress M in 2021 marked the start of the decline of the game business.
-
Operating breakeven lost. FY2024's small operating profit (KRW 0.97 bn) turned into a KRW 2.29 bn loss in FY2025. With fixed costs for a listed entity and very small revenue, operating leverage works against the company.
-
Below-the-line losses dominate. In FY2024 the pre-tax loss (−KRW 26.3 bn) was about 27x larger than operating profit. Management said the FY2025 loss narrowed thanks to higher finance income and lower expenses.
-
Balance sheet de-levered, equity flat. Liabilities fell from KRW 33.0 bn to KRW 13.9 bn in FY2025. That fits with the partial BW redemption and CB-sale proceeds. Equity rose slightly despite the net loss because share capital increased by KRW 10 bn (20 m new shares; the issuance event was not identified).
-
Confirmation requires the H1 2026 semi-annual report.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Layer | Entity | Role / relationship | Source |
|---|---|---|---|
Ultimate controller | Kim Jae-seop (김재섭) | 100% owner of G-Base; Aprogen founder; director of APTOCROM | Asia Economy, 6 Feb 2020; AGM results 30 Mar 2026 |
Top holding company | G-Base Co. (지베이스) | Largest shareholder of Aprogen (25.81% per Newstomato) | Newstomato (IB Tomato) |
Listed parent | Aprogen Inc. (KOSPI 007460) | Largest shareholder of APTOCROM (71.66%, Aug 2025) | DigitalToday, 22 Aug 2025 |
Listed sister | Aprogen Biologics Inc. (KOSPI 003060; formerly Aprogen Pharmaceuticals) | Former 20.06% holder of APTOCROM; CMO / Osong plant | Asia Economy, 11 Aug 2025; MarketScreener |
Affiliate | Nexconics (넥스코닉스) | Group IT affiliate; 9.52% holder of Aprogen; subscriber to the May 2026 APTOCROM placement | Asia Economy, 6 Feb 2020; Newstomato; DigitalToday, 28 Apr 2026 |
Subject company | APTOCROM Inc. (KOSDAQ 109960) | Pharmaceutical distribution, leasing, group funding | Filings |
Subsidiaries of APTOCROM | — | AGM results disclosure, 30 Mar 2026 | — |
Revenue by Segment
| Metric | FY2024 | FY2025 |
|---|---|---|
Consolidated revenue (KRW Bn) | 16.40 | 9.81 |
Parent-only (separate) revenue (KRW Bn) | — | 7.40 |
Implied subsidiaries' net contribution to revenue (KRW Bn, computed) | — | 2.41 |
Parent-only operating income (KRW Bn) | — | -1.16 |
Implied subsidiaries' operating income (KRW Bn, computed) | — | -1.13 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2024 | FY2025 |
|---|---|---|
Revenue (KRW Bn) | 16.40 | 9.81 |
Operating income (KRW Bn) | 0.97 | -2.29 |
Pre-tax income from continuing ops (KRW Bn) | -26.34 | -6.43 |
Net income (KRW Bn) | -28.02 | -5.63 |
Basic EPS (KRW, pre-reverse-split) | — | -26 |
Dividends per share (KRW) | 0 | 0 |
Operating margin (%) | 5.9 | -23.3 |
Net margin (%) | -170.9 | -57.4 |
Margin Analysis (%)
| Metric | FY2025 |
|---|---|
Revenue growth YoY (%) | -40.2 |
Revenue CAGR FY2019–FY2025 (%, computed) | -12.5 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (KRW Bn) | 334.89 | 320.46 |
Total liabilities (KRW Bn) | 33.04 | 13.89 |
Total equity (KRW Bn) | 301.86 | 306.57 |
Share capital (KRW Bn) | 100.39 | 110.39 |
Shares outstanding (m, computed from capital at KRW 500 par) | 200.79 | 220.79 |
Liabilities to equity (%) | 10.9 | 4.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansReturns & Leverage Ratios
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Dividends paid (KRW Bn) | — | 0 | 0 |
Equity raised — public offering (KRW Bn, planned size) | — | 50.0 | — |
Biosimilar cost-sharing outflow committed (KRW Bn) | 50.0 | 35.0 | 35.0 |
Proceeds received from sale of Aprogen 27th CB (KRW Bn, contractual schedule) | — | 17.0 | 7.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
ROE (%, computed on ending/average equity) | -9.3 | -1.8 |
ROA (%, computed) | -8.4 | -1.7 |
Asset turnover (x, computed) | 0.05 | 0.03 |
Liabilities / equity (x) | 0.11 | 0.05 |
Income Statement
| Metric | FY2018 | FY2019 |
|---|---|---|
Revenue (KRW Bn) | 19.4 | 21.9 |
Operating income (KRW Bn) | -0.21 | -0.77 |
Net income (KRW Bn) | — | -9.39 |
Share Price History
| Date | Reported price (KRW) | Basis | Post-split equivalent (KRW) | Source |
|---|---|---|---|---|
19 May 2025 | 341 | Pre-split | 6,820 | Simply Wall St |
11 Aug 2025 | 455 | Pre-split (limit-up) | 9,100 | Asia Economy |
22 Aug 2025 | 398 | Pre-split | 7,960 | DigitalToday |
23 Feb 2026 | 193 | Pre-split | 3,860 | DigitalToday |
31 Mar 2026 | 164 | Pre-split | 3,280 | DigitalToday |
28 Apr 2026 | 178 | Pre-split | 3,560 | DigitalToday |
15 Jul 2026 | 1,696 | Post-split | 1,696 | Asia Economy quote |
13 Oct 2026 | 1,890 | Post-split | 1,890 | Judal |
Metric | 1 year | 3 years | 5 years | — |
Share-price change (%) | not computed | not computed | not computed | — |
Valuation Multiples
| Multiple | APTOCROM | Basis |
|---|---|---|
Market cap (KRW Bn) | 28.5 | Judal, 13–14 Oct 2026 |
P/B (x) | 0.09 | KRW 28.5 bn ÷ FY2025 equity KRW 306.6 bn (Judal shows 0.08x) |
P/S (x) | 2.9 | ÷ FY2025 revenue KRW 9.81 bn |
P/E (x, trailing) | 0.57–0.58 (Judal); FY2025 basis negative / not meaningful | — |
EV/EBITDA (x) | Not meaningful (EBITDA not disclosed; negative operating income) | — |
Capital Markets
| Item | Status | Source |
|---|---|---|
Sell-side analyst consensus | None identified. Judal "AI equity research" pages (Buy, KRW 9,600 targets, etc.) are machine-generated and are not treated as analyst consensus | Judal, Oct 2026 |
Dividend history / policy | No dividend record | Simply Wall St |
Buyback authorizations | None disclosed. Simply Wall St shows a buyback yield of −59.3%, reflecting net share issuance | Simply Wall St |
Debt maturity profile | 6th BW: maturity 25 Jul 2026 (partially redeemed by Q1 2026); bank short-term borrowings KRW 3.5 bn (KB) + KRW 2.0 bn (Hana), maturities not disclosed | KIND Q1 2026 excerpt |
Share count history | ~113.8 m (pre-Oct 2024, computed) → 200.79 m (end-2024) → 220.79 m (end-2025) → 11.04 m (post 20:1) → ~15.13 m (post placement, computed) | Asia Economy, 8 Oct 2024; capital figures from disclosures |
Analyst Conclusions
Guidance and expectations
Management has published no revenue or earnings guidance. There is no consensus. The only forward-looking statements on record are (i) the parent's AP096 timeline (clinical work to 2027, launch as early as 2028) and (ii) the company's 2024 expectation of dividend receipts from 2027 and full recovery of the investment around 2030 if development succeeds (Asia Economy, 8 Oct 2024; Dealsite, 20 Sep 2024).
Bull case
-
Deep asset discount. Book equity of KRW 306.6 bn against a market cap of about KRW 28.5 bn (P/B ~0.09x). Even heavy haircuts on related-party assets could leave value above the current price.
-
Cash conversion of the CB sale. Collecting the KRW 16 bn balance on the Aprogen 27th CB would equal over half of the current market cap in cash.
-
Biosimilar optionality. If AP063/AP096 reach market (regulatory easing cited by the parent), contractual sales-linked dividends could exceed the company's entire current revenue base.
Bear case
-
Circularity of value. Much of the asset base appears to consist of claims on, or securities of, a parent that loses about KRW 97.5 bn a year at the operating level (TTM). Book value may overstate recoverable value, as the FY2024 KRW 26 bn below-the-line loss suggests.
-
Minority dilution as the funding model. The 2024 offering (~87% new shares) and the 2026 affiliate placement (~37%) show repeated recapitalizations at minority shareholders' expense. A 20:1 consolidation was also needed to escape penny-stock status.
-
Shrinking operations and narrative churn. Revenue fell 55% between FY2019 and FY2025. There have been three corporate names in about 18 months, and a crypto charter has produced no disclosed operations, which signals strategic drift.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Expected timing |
|---|---|---|
| H1 2026 semi-annual and Q3 2026 quarterly reports | Verify the positive TTM earnings implied by aggregators; identify the gain source | Released Aug 2026; Q3 due by mid-Nov 2026 |
| Final settlement of the Aprogen 27th CB sale (KRW 16 bn balance) | Liquidity and asset quality | Due 17 Apr 2026, extendable to 30 Jun 2026; confirm outcome |
| Disclosure of the acquisition funded by the KRW 12 bn placement | Strategic direction; related-party character | Pending |
| 6th-series BW maturity (25 Jul 2026) | Confirm full repayment | Passed; confirm |
| AP096 / AP063 clinical and regulatory progress at Aprogen | Underpins the value of biosimilar claims | Ongoing |
| Any crypto/blockchain licence, partnership or revenue | Tests credibility of the 2025 pivot | Not scheduled |
| FY2026 business report and AGM (≈Mar 2027) | Audited asset values; board changes | Q1 2027 |
| Lock-up expiry on Nexconics placement shares | Potential supply | ~17 Jun 2027 |
Analyst verdict
APTOCROM, formerly Aprogen Healthcare & Games and then AP Healthcare, should not be analyzed as a pharmaceutical distributor. Its operating business is too small to anchor value: KRW 9.8 bn of revenue and an operating loss of KRW 2.3 bn in FY2025. Seventeen or eighteen employees cannot credibly sustain an independent strategy in Korean pharmaceutical wholesale, a market dominated by large-scale private distributors. The listed shell's real function since entering the Aprogen group in 2017–2018 has been as a capital conduit. It raised equity and debt from public markets and redeployed the proceeds into parent and affiliate instruments: Aprogen KIC's KRW 70 bn CB in 2018, KRW 50 bn for AP063 in 2023, KRW 70 bn committed to AP096 in 2024–2025, and the KRW 40 bn Aprogen 27th CB, now being sold in delayed installments.
The investment debate therefore reduces to one question: how much of roughly KRW 307 bn of book equity is recoverable cash, rather than accounting value attached to a parent burning close to KRW 100 bn a year at the operating level? The market's answer, a P/B near 0.09x, is a heavy discount. That discount looks rational given FY2024's KRW 26 bn non-operating loss, the rescheduling of CB receipts, affiliate ownership near 80% and only one independent director. The 2025 crypto rebrand and 2026 reverse split addressed the share price and exchange-compliance optics, not fundamentals.
Upside exists. A clean collection of the KRW 16 bn CB balance or an AP096/AP063 commercial milestone could re-rate the shares sharply from such a depressed base. Those catalysts, however, sit largely outside the company's control and depend on a financially strained parent. Pending verification of H1 2026 earnings and the undisclosed acquisition target, the profile is best described as a high-risk, related-party-dependent special situation with weak minority protections.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Tenure / status | Background (as disclosed) | Born |
|---|---|---|---|---|
Kim Jeong-chul (김정출) | Representative Director (CEO) | — | — | — |
Kim Jae-seop (김재섭) | Inside (executive) director | Re-elected 30 Mar 2026, 3-year term | Inside director of G-Base (his 100%-owned holding company); founder of Aprogen (est. 2000, KAIST-linked) and its chairman/CEO | Jan 1963 |
Kang Seong-ho (강성호) | Inside director | Newly elected 30 Mar 2026, 3-year term | — | — |
Lee Jong-seop (이종섭) | Outside (independent) director | Re-elected 30 Mar 2026, 3-year term; 6 years cumulative tenure including the new term | Head director of Ansan Yonsei Hospital | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date / basis | Source |
|---|---|---|---|
Aprogen Inc. | 71.66% | 21 Aug 2025, after an 18 Aug 2025 off-market purchase of 40,269,859 shares at KRW 317 | DigitalToday, 22 Aug 2025 |
Aprogen Inc. (prior) | 53.42% | 26 Jun 2025 report basis | DigitalToday, 22 Aug 2025 |
Aprogen Inc. / Aprogen Biologics (alternate prior figures) | 48.78% / 20.06% | Reported 11 Aug 2025 (data date likely pre-transfer) | Asia Economy, 11 Aug 2025 |
Aprogen Inc. (2024) | ~42% | Sep 2024 | Dealsite, 20 Sep 2024 |
Nexconics (affiliate) | ~27.0% (computed) | Post-May-2026 placement of 4,092,770 shares out of ~15.13 m total; 1-year lock-up | DigitalToday, 28 Apr 2026 (computation by author) |
Aprogen Inc. (post-placement, computed) | ~52.3% (computed) | 71.66% × 11,039,463 ÷ 15,132,233; assumes no other changes | Author computation |
Combined affiliates (computed) | ~79% | Post-placement | Author computation |
Competitive Landscape
Competitors by Segment
| Arena | Competitor / comparator | Relevance | Comparative revenue | Source / note |
|---|---|---|---|---|
Korean pharmaceutical wholesale | Geo-Young (지오영) | Largest Korean pharmaceutical wholesaler (private) | — | — |
Korean pharmaceutical wholesale | Baekje Pharm (백제약품) | Major private wholesaler | — | Same |
Korean pharmaceutical wholesale | Incheon Pharm (인천약품) | Regional wholesaler | — | Same |
Korean pharmaceutical wholesale | Boksan Nice (복산나이스) | Regional wholesaler | — | Same |
Korean pharmaceutical wholesale | TJ Pharm (티제이팜) | Wholesaler | — | Same |
KOSDAQ crypto-pivot cohort | Hyper Corporation (KOSDAQ 065650) | Peer in "virtual-asset pivot" theme | — | Asia Economy, 11 Aug 2025 |
KOSDAQ crypto-pivot cohort | Parataxis Korea (KOSDAQ 288330) | Same; largest shareholder became a foreign crypto firm | — | Same |
KOSDAQ crypto-pivot cohort | Someage (KOSDAQ 208640) | Same; charter amended for crypto | — | Same |
Group comparator | Aprogen Biologics (KOSPI 003060) | Sister listed affiliate | TTM revenue ~KRW 68.6 bn; TTM operating loss ~KRW 57.0 bn | ValueLine (26.1Q) |
Group comparator | Aprogen Inc. (KOSPI 007460) | Parent | TTM revenue ~KRW 127.3 bn; TTM operating loss ~KRW 97.5 bn | ValueLine (26.2Q) |
Peer Comparison FY2025
| Metric | APTOCROM FY2025 | Aprogen (TTM 26.2Q) | Aprogen Biologics (TTM 26.1Q) |
|---|---|---|---|
Revenue (KRW Bn) | 9.81 | 127.3 | 68.6 |
Operating margin (%) | -23.3 | -76.6 | -83.1 |
Market cap (KRW Bn) | ~28.5 (Oct 2026) | ~67 (27 Aug 2026) | ~29.3 (25 Jun 2026) |
R&D intensity | — | Not disclosed here | Not disclosed here |
“—” = not publicly disclosed.
Recent Developments
Items not identified in the period: product launches, contract wins, layoffs, litigation and regulatory sanctions.



